A. Alikasifoglu Et Al. , "Is conventional treatment still the first choice in pediatric patients with PHEX mutations in an era of monoclonal FGF-23 antibody?," HORMONE RESEARCH IN PAEDIATRICS , vol.94, no.SUPPL 1, pp.210-211, 2021
Alikasifoglu, A. Et Al. 2021. Is conventional treatment still the first choice in pediatric patients with PHEX mutations in an era of monoclonal FGF-23 antibody?. HORMONE RESEARCH IN PAEDIATRICS , vol.94, no.SUPPL 1 , 210-211.
Alikasifoglu, A., Unsal, Y., Gonc, N., Ozon, A., Kandemir, N., & Alikasifoglu, M., (2021). Is conventional treatment still the first choice in pediatric patients with PHEX mutations in an era of monoclonal FGF-23 antibody?. HORMONE RESEARCH IN PAEDIATRICS , vol.94, no.SUPPL 1, 210-211.
Alikasifoglu, AYFER Et Al. "Is conventional treatment still the first choice in pediatric patients with PHEX mutations in an era of monoclonal FGF-23 antibody?," HORMONE RESEARCH IN PAEDIATRICS , vol.94, no.SUPPL 1, 210-211, 2021
Alikasifoglu, AYFER Et Al. "Is conventional treatment still the first choice in pediatric patients with PHEX mutations in an era of monoclonal FGF-23 antibody?." HORMONE RESEARCH IN PAEDIATRICS , vol.94, no.SUPPL 1, pp.210-211, 2021
Alikasifoglu, A. Et Al. (2021) . "Is conventional treatment still the first choice in pediatric patients with PHEX mutations in an era of monoclonal FGF-23 antibody?." HORMONE RESEARCH IN PAEDIATRICS , vol.94, no.SUPPL 1, pp.210-211.
@article{article, author={AYFER ALİKAŞİFOĞLU Et Al. }, title={Is conventional treatment still the first choice in pediatric patients with PHEX mutations in an era of monoclonal FGF-23 antibody?}, journal={HORMONE RESEARCH IN PAEDIATRICS}, year=2021, pages={210-211} }